Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lilly’s dominance
Early indications from the launch of Novo Nordisk’s oral Wegovy and Eli Lilly’s Foundayo are prompting investors to reassess the competitive landscape for GLP-1 pills. Novo Nordisk’s head start in the oral...
Read More